check_circleStudy Completed

Cardiovascular Agents

To establish the bioequivalence between riociguat tablet 0.5 mg intended to be marketed (#501) and riociguat tablet 0.5 mg used for clinical samples (#511) in Japanese healthy adult male subjects.

Trial purpose

The study will be conducted in a single-center, randomized, non-blinded, two-way crossover study in Japanese healthy adult male subjects. 24 subjects will be selected among the subjects undergoing the screening examination conducted within 4 weeks before drug administration of period 1. Single oral doses of riociguat tablet 0.5 mg #501 and riociguat tablet 0.5 mg #511 will be given to selected 24 subjects under the fasting condition with a wash-out interval of 7 days or longer.
One day before the drug administration of each period the subjects will be admitted to the clinical site. During the hospitalization, blood samples for riociguat and its metabolite BAY 60-4552 (M-1) pharmacokinetics will be taken, and the subjects will undergo several tests for safety up to 72 hrs after the administration. Follow up examination will be conducted between Day 7 and Day 10 of period 2.

Key Participants Requirements

Sex

Male

Age

20 - 30 Years

Trial summary

Enrollment Goal
24
Trial Dates
August 2010 - September 2010
Phase
Phase 1
Could I Receive a placebo
No
Products
Adempas (Riociguat, BAY63-2521)
Accepts Healthy Volunteer
Yes

Where to participate

StatusInstitutionLocation
Completed
Osaka Pharmacology Clinical Research HospitalOsaka, 532-0003, Japan

Primary Outcome

  • Bioequivalence between two tablet formulations of Riociguat assessed using AUC and C(max) calculated from plasma riociguat concentration
    date_rangeTime Frame:
    up tp 72 hours
    enhanced_encryption
    Safety Issue:
    No

Trial design

Bioequivalence study of two tablet formulations of riociguat (BAY 63-2521) 0.5 mg – Randomized, non-blind, two-way crossover study to establish the bioequivalence between tablets intended to be marketed and clinical samples used in Phase III studies in Japanese healthy adult male subjects.
Trial Type
Interventional
Intervention Type
Drug
Trial Purpose
Other
Allocation
Randomized
Blinding
Open Label
Assignment
Crossover Assignment
Trial Arms
2